中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 11
Nov.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(11): 2705-2709

Predictive indicators for the efficacy of targeted therapy/immunotherapy for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.11.028

  • Department of Gastroenterology，Xijing Hospital，Air Force Medical University，Xi’an 710032，China

Research funding:

National Natural Science Foundation of China (81870421)

More Information
  • Corresponding author: ZHOU Xinmin， zhouxmm@fmmu.edu.cn （ORCID： 0000-0002-6521-9885）
  • Received Date: 2023-01-16
  • Accepted Date: 2023-06-09
  • Published Date: 2023-11-28
    Abstract
  • Hepatocellular carcinoma （HCC） is a common malignancy in China， and molecular-targeted drugs and immune checkpoint inhibitors for the treatment of advanced HCC are currently a research hotspot； however， there are large individual differences in the treatment outcome of advanced HCC. In order to further screen for the population with benefits from such treatment， predict treatment outcome， and improve disease prognosis， this article summarizes the studies on predicting the efficacy of targeted therapy/immunotherapy for HCC， so as to provide a reference for developing individualized treatment regimens for patients with advanced HCC.

     

    • FullText(HTML)
  • loading
    • References(36)
  • [1]
    ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394( 10204): 1145- 1158. DOI: 10.1016/S0140-6736(19)30427-1.
    [2]
    RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77( 6): 1598- 1606. DOI: 10.1016/j.jhep.2022.08.021.
    [3]
    General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [4]
    LI SS, GUO ZT, CHEN ZB, et al. Research advances in systemic therapy for advanced hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37( 12): 2943- 2946. DOI: 10.3969/j.issn.1001-5256.2021.12.044.

    李世思, 郭志唐, 陈章彬, 等. 晚期肝细胞癌系统治疗的研究进展[J]. 临床肝胆病杂志, 2021, 37( 12): 2943- 2946. DOI: 10.3969/j.issn.1001-5256.2021.12.044.
    [5]
    KUZUYA T, ISHIGAMI M, ITO T, et al. Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment[J]. Hepatol Res, 2019, 49( 9): 1054- 1065. DOI: 10.1111/hepr.13358.
    [6]
    HERSBERGER L, BARGETZI L, BARGETZI A, et al. Nutritional risk screening(NRS 2002) is a strong and modifiable predictor risk score for short-term and long-term clinical outcomes: secondary analysis of a prospective randomised trial[J]. Clin Nutr, 2020, 39( 9): 2720- 2729. DOI: 10.1016/j.clnu.2019.11.041.
    [7]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68( 6): 394- 424. DOI: 10.3322/caac.21492.
    [8]
    KIM B, KIM SS, CHO SW, et al. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma[J]. Eur Radiol, 2021, 31( 4): 2507- 2517. DOI: 10.1007/s00330-020-07357-9.
    [9]
    NICOLAS-BOLUDA A, VAQUERO J, VIMEUX L, et al. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment[J]. Elife, 2021, 10: e58688. DOI: 10.7554/eLife.58688.
    [10]
    YUAN G, XIE F, SONG Y, et al. Hepatic tumor stiffness measured by shear wave elastography is prognostic for HCC progression following treatment with anti-PD-1 antibodies plus lenvatinib: A retrospective analysis of two independent cohorts[J]. Front Immunol, 2022, 13: 868809. DOI: 10.3389/fimmu.2022.868809.
    [11]
    WANG F, QIN S, SUN X, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial[J]. J Hematol Oncol, 2020, 13( 1): 47. DOI: 10.1186/s13045-020-00886-2.
    [12]
    DÍAZ-GONZÁLEZ Á, SANDUZZI-ZAMPARELLI M, SAPENA V, et al. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib[J]. Aliment Pharmacol Ther, 2019, 49( 5): 482- 491. DOI: 10.1111/apt.15088.
    [13]
    MAO J, WANG D, LONG J, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers[J]. J Immunother Cancer, 2021, 9( 12): e003334. DOI: 10.1136/jitc-2021-003334.
    [14]
    DAVID LA, MAURICE CF, CARMODY RN, et al. Diet rapidly and reproducibly alters the human gut microbiome[J]. Nature, 2014, 505( 7484): 559- 563. DOI: 10.1038/nature12820.
    [15]
    GALLE PR, FOERSTER F, KUDO M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma[J]. Liver Int, 2019, 39( 12): 2214- 2229. DOI: 10.1111/liv.14223.
    [16]
    SHAO YY, LIU TH, HSU C, et al. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma[J]. Liver Int, 2019, 39( 11): 2184- 2189. DOI: 10.1111/liv.14210.
    [17]
    ZHU AX, KANG YK, YEN CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20( 2): 282- 296. DOI: 10.1016/S1470-2045(18)30937-9.
    [18]
    AO H, XIN Z, JIAN Z. Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma[J]. Biomark Res, 2021, 9( 1): 91. DOI: 10.1186/s40364-021-00348-y.
    [19]
    YUE C, JIANG Y, LI P, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy[J]. Oncoimmunology, 2018, 7( 7): e1438111. DOI: 10.1080/2162402X.2018.1438111.
    [20]
    WINOGRAD P, HOU S, COURT CM, et al. Hepatocellular carcinoma-circulating tumor cells expressing PD-L1 are prognostic and potentially associated with response to checkpoint inhibitors[J]. Hepatol Commun, 2020, 4( 10): 1527- 1540. DOI: 10.1002/hep4.1577.
    [21]
    SCHEINER B, POMEJ K, KIRSTEIN MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy-development and validation of the CRAFITY score[J]. J Hepatol, 2022, 76( 2): 353- 363. DOI: 10.1016/j.jhep.2021.09.035.
    [22]
    YOSHIDA T, ICHIKAWA J, GIUROIU I, et al. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma[J]. J Immunother Cancer, 2020, 8( 1): e000234. DOI: 10.1136/jitc-2019-000234.
    [23]
    JIMENEZ RV, KUZNETSOVA V, CONNELLY AN, et al. C-reactive protein promotes the expansion of myeloid derived cells with suppressor functions[J]. Front Immunol, 2019, 10: 2183. DOI: 10.3389/fimmu.2019.02183.
    [24]
    AKAMINE T, TAKADA K, TOYOKAWA G, et al. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers[J]. Surg Oncol, 2018, 27( 1): 88- 94. DOI: 10.1016/j.suronc.2018.01.002.
    [25]
    BRUIX J, CHENG AL, MEINHARDT G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies[J]. J Hepatol, 2017, 67( 5): 999- 1008. DOI: 10.1016/j.jhep.2017.06.026.
    [26]
    MEI J, SUN XQ, LIN WP, et al. Comparison of the prognostic value of inflammation-based scores in patients with hepatocellular carcinoma after anti-PD-1 therapy[J]. J Inflamm Res, 2021, 14: 3879- 3890. DOI: 10.2147/JIR.S325600.
    [27]
    DHARMAPURI S, ÖZBEK U, LIN JY, et al. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy[J]. Cancer Med, 2020, 9( 14): 4962- 4970. DOI: 10.1002/cam4.3135.
    [28]
    HARDING JJ, NANDAKUMAR S, ARMENIA J, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies[J]. Clin Cancer Res, 2019, 25( 7): 2116- 2126. DOI: 10.1158/1078-0432.CCR-18-2293.
    [29]
    MASUDA M, CHEN WY, MIYANAGA A, et al. Alternative mammalian target of rapamycin(mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling[J]. Mol Cell Proteomics, 2014, 13( 6): 1429- 1438. DOI: 10.1074/mcp.M113.033845.
    [30]
    LLOVET JM, MONTAL R, SIA D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2018, 15( 10): 599- 616. DOI: 10.1038/s41571-018-0073-4.
    [31]
    SCHULZE K, IMBEAUD S, LETOUZÉ E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J]. Nat Genet, 2015, 47( 5): 505- 511. DOI: 10.1038/ng.3252.
    [32]
    PINYOL R, SIA D, LLOVET JM. Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC[J]. Clin Cancer Res, 2019, 25( 7): 2021- 2023. DOI: 10.1158/1078-0432.CCR-18-3778.
    [33]
    SIA D, JIAO Y, MARTINEZ-QUETGLAS I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features[J]. Gastroenterology, 2017, 153( 3): 812- 826. DOI: 10.1053/j.gastro.2017.06.007.
    [34]
    LIU CQ, XU J, ZHOU ZG, et al. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma[J]. Br J Cancer, 2018, 119( 1): 80- 88. DOI: 10.1038/s41416-018-0144-4.
    [35]
    EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389( 10088): 2492- 2502. DOI: 10.1016/S0140-6736(17)31046-2.
    [36]
    YAU T, PARK JW, FINN RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma(CheckMate 459): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23( 1): 77- 90. DOI: 10.1016/S1470-2045(21)00604-5.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (407) PDF downloads(54) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return